ALMS ▲ +3.7% - Alumis Inc.
$ALMS - Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
09-OCT-2026 04:00 AM ET
Share this post
More filings for $ALMS
ALMS ▼ -0.6% - Alumis Inc.Sep 4, 2026ALMS ▲ +1.9% - Alumis Inc.Sep 2, 2026ALMS ▼ -2.0% - Alumis Inc.Sep 1, 2026ALMS ▼ -2.0% - Alumis Inc.Sep 1, 2026ALMS - Alumis Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026$ALMS SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $ALMS filing history →💬 Comments
Loading comments…
Leave a comment